These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32037892)

  • 1. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease.
    Hashweh NN; Bartochowski Z; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2020 Apr; 21(6):619-627. PubMed ID: 32037892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
    Schelter BO; Shiells H; Baddeley TC; Rubino CM; Ganesan H; Hammel J; Vuksanovic V; Staff RT; Murray AD; Bracoud L; Riedel G; Gauthier S; Jia J; Bentham P; Kook K; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2019; 72(3):931-946. PubMed ID: 31658058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
    Riedel G; Klein J; Niewiadomska G; Kondak C; Schwab K; Lauer D; Magbagbeolu M; Steczkowska M; Zadrozny M; Wydrych M; Cranston A; Melis V; Santos RX; Theuring F; Harrington CR; Wischik CM
    Curr Alzheimer Res; 2020; 17(3):285-296. PubMed ID: 32091331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.
    Wischik CM; Bentham P; Gauthier S; Miller S; Kook K; Schelter BO
    J Prev Alzheimers Dis; 2022; 9(4):780-790. PubMed ID: 36281683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.
    Seripa D; Solfrizzi V; Imbimbo BP; Daniele A; Santamato A; Lozupone M; Zuliani G; Greco A; Logroscino G; Panza F
    Expert Rev Neurother; 2016; 16(3):259-77. PubMed ID: 26822031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
    Shiells H; Schelter BO; Bentham P; Baddeley TC; Rubino CM; Ganesan H; Hammel J; Vuksanovic V; Staff RT; Murray AD; Bracoud L; Wischik DJ; Riedel G; Gauthier S; Jia J; Moebius HJ; Hardlund J; Kipps CM; Kook K; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2020; 75(2):501-519. PubMed ID: 32280089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
    Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
    J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
    Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
    Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
    Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
    Wilcock GK; Gauthier S; Frisoni GB; Jia J; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Schelter BO; Wischik DJ; Davis CS; Staff RT; Vuksanovic V; Ahearn T; Bracoud L; Shamsi K; Marek K; Seibyl J; Riedel G; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2018; 61(1):435-457. PubMed ID: 29154277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).
    Al-Hilaly YK; Pollack SJ; Rickard JE; Simpson M; Raulin AC; Baddeley T; Schellenberger P; Storey JMD; Harrington CR; Wischik CM; Serpell LC
    J Mol Biol; 2018 Oct; 430(21):4119-4131. PubMed ID: 30121297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease.
    Baddeley TC; McCaffrey J; Storey JM; Cheung JK; Melis V; Horsley D; Harrington CR; Wischik CM
    J Pharmacol Exp Ther; 2015 Jan; 352(1):110-8. PubMed ID: 25320049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks.
    Schwab K; Melis V; Harrington CR; Wischik CM; Magbagbeolu M; Theuring F; Riedel G
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
    Harrington CR; Storey JM; Clunas S; Harrington KA; Horsley D; Ishaq A; Kemp SJ; Larch CP; Marshall C; Nicoll SL; Rickard JE; Simpson M; Sinclair JP; Storey LJ; Wischik CM
    J Biol Chem; 2015 Apr; 290(17):10862-75. PubMed ID: 25759392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease.
    Yuksel M; Biberoglu K; Onder S; Akbulut KG; Tacal O
    Biochimie; 2018 Mar; 146():105-112. PubMed ID: 29248542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
    Kondak C; Riedel G; Harrington CR; Wischik CM; Klein J
    J Neurochem; 2022 Jan; 160(2):172-184. PubMed ID: 34855998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.